Updated: January 26, 2026
How Does Jublia Work? Mechanism of Action Explained in Plain English
Author
Peter Daggett

Summarize with AI
- What Is Toenail Fungus and What Makes It Hard to Treat?
- Step 1: Jublia Penetrates the Nail — Better Than Most Topicals
- Step 2: Jublia Inhibits 14α-Demethylase — The Fungal Cell's Key Enzyme
- Step 3: Without Ergosterol, the Fungal Cell Dies
- Why Does Jublia Target Fungal Cells But Not Human Cells?
- Why Does Jublia Take So Long to Work?
- Understanding Jublia's Mechanism Makes Adherence Easier
How does Jublia kill toenail fungus? Here's a plain-English explanation of how efinaconazole works at the cellular level — and why it's so effective as a topical.
Jublia (efinaconazole) is more than just "medicine you put on your nail." It's a precisely engineered antifungal compound designed to penetrate hard nail tissue and destroy the fungi causing your infection at a cellular level. Here's how it actually works — explained in language that doesn't require a medical degree.
What Is Toenail Fungus and What Makes It Hard to Treat?
Toenail fungus (onychomycosis) is caused by a group of fungi called dermatophytes — most commonly Trichophyton rubrum and Trichophyton mentagrophytes. These organisms invade the nail plate and nail bed, setting up shop in and under the nail where they're protected from most treatments by the hard keratin structure of the nail itself.
This is what makes topical antifungals historically difficult to use: most compounds bind tightly to keratin (the protein in nails), which prevents them from penetrating deep enough to reach the infection. Jublia was specifically designed to overcome this barrier.
Step 1: Jublia Penetrates the Nail — Better Than Most Topicals
Efinaconazole was discovered by Japanese pharmaceutical company Kaken Pharmaceutical and was engineered to have low binding affinity to keratin. Because it doesn't bind tightly to the nail's keratin proteins, it remains free in solution and can penetrate deep into the nail plate and nail bed — reaching the site where the fungal infection actually lives.
This is one of Jublia's most clinically significant advantages over older topical antifungals like ciclopirox nail lacquer, which has strong keratin binding and limited penetration. Studies comparing efinaconazole, tavaborole, and ciclopirox have shown that efinaconazole achieves superior fungicidal activity in the presence of keratin.
Step 2: Jublia Inhibits 14α-Demethylase — The Fungal Cell's Key Enzyme
Once inside the nail and at the site of infection, efinaconazole gets to work at the molecular level. Like all azole antifungals (fluconazole, itraconazole, ketoconazole), efinaconazole works by blocking a fungal enzyme called lanosterol 14α-demethylase — also known as CYP51.
This enzyme is essential for fungi to produce ergosterol — a compound that makes up the fungal cell membrane (similar to how cholesterol works in human cell membranes). Ergosterol gives the fungal cell wall its structural integrity, allowing the fungus to control what enters and exits the cell.
Step 3: Without Ergosterol, the Fungal Cell Dies
When 14α-demethylase is blocked, the fungus cannot synthesize ergosterol. Instead, toxic sterol intermediates (such as lanosterol) accumulate in the cell membrane. The result:
The fungal cell membrane becomes structurally unstable and leaky
Critical cellular components leak out
The fungus can no longer grow or divide normally
At sufficient concentrations, the fungal cell dies — this is called fungicidal activity
In laboratory and animal studies, efinaconazole demonstrated potent fungicidal activity — meaning it actually kills the fungus rather than just slowing its growth. This is more than "fungistatic" action (just preventing new growth) and is one reason Jublia is among the more effective topical options available.
Why Does Jublia Target Fungal Cells But Not Human Cells?
Human cells don't use ergosterol — they use cholesterol instead. The 14α-demethylase enzyme in human cells (CYP51) is significantly different in structure from the fungal version. Efinaconazole is designed to selectively bind to the fungal CYP51 enzyme with much greater affinity than the human version.
This selectivity is what makes azole antifungals generally safe for humans. The minimal systemic absorption of Jublia (it stays mostly on the nail surface with very little entering the bloodstream) further reduces the risk of any systemic effects.
Why Does Jublia Take So Long to Work?
Even though Jublia starts killing fungal cells from the first application, visible results take a long time. That's because the drug doesn't make infected nail tissue "un-infect" — instead, it clears the active fungal infection so that healthy new nail tissue can grow in and replace the damaged, fungal-infected nail.
Toenails grow at roughly 1 mm per month — far slower than fingernails. A complete toenail replacement takes 12–18 months. That's why even a highly effective drug needs to be applied daily for 48 weeks — you need to continuously suppress the fungal infection while healthy nail slowly grows in. Stopping early, even if results seem good, risks the fungus rebounding before the nail has fully cleared.
Understanding Jublia's Mechanism Makes Adherence Easier
Knowing how Jublia works can help you stay on track with treatment. The medication is actively fighting the infection from day one — even if you can't see it. For a complete patient guide, see what is Jublia and how to use it. And if you're struggling to access your Jublia prescription, medfinder can help you find a pharmacy that can fill it.
Frequently Asked Questions
Jublia is fungicidal at therapeutic concentrations — meaning it actually kills the fungal organisms rather than just inhibiting their growth. In laboratory studies with Trichophyton mentagrophytes in the presence of keratin, efinaconazole achieved complete mycological eradication within 7–14 days of exposure. This is more powerful than fungistatic action (just slowing growth).
Jublia penetrates the nail more effectively than ciclopirox because it has low keratin binding affinity — meaning it doesn't get trapped in the nail protein and remains free to reach the infection site. Ciclopirox binds more tightly to keratin, reducing penetration and antifungal activity at the site of infection.
Systemic absorption of Jublia is minimal. In studies of patients applying it daily to all 10 toenails for 28 days, plasma concentrations were very low (mean Cmax 0.67 ng/mL on Day 28). At this level, no systemic toxicity has been observed. This low systemic exposure is also why Jublia has no significant drug interactions, unlike oral azole antifungals.
Human cells use cholesterol in their cell membranes — not ergosterol. The 14α-demethylase enzyme targeted by efinaconazole is structurally different in fungi vs. humans, so the drug selectively targets fungal cells with much greater potency than human cells. The minimal systemic absorption of topical Jublia further limits any potential interaction with human CYP51.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Jublia also looked for:
More about Jublia
31,889 have already found their meds with Medfinder.
Start your search today.





